Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

MedTech Summit
7 -10 June 2027
DoubleTree by Hilton Brussels CityAttend In-Person or 100% Digitally

Stay Ahead of the Curve

Breaking News in Medtech: Industry News & Reports

Keep pace with the latest breakthroughs in Medtech, strategic partnerships, and investment trends from BioXconomy—your trusted source for industry intelligence.

Partnerships & Collaborations

Discover how industry leaders are collaborating to advance Medtech as well as the latest regulatory requirements.

Europe's life sciences sector gets an $815m vote of confidence from Sofinnova

Paris-based Sofinnova Partners has announced the final close of Sofinnova Crossover II at €725 million ($815 million), exceeding its original target. The oversubscribed raise underscores growing investor confidence in the firm's strategy of backing late-stage life sciences companies positioned to become global leaders, with a primary focus on Europe and selective investments in the US and other international markets.

An article from our editorial partner, BioXconomy.

Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy

Firms transition from manual processes to systems with built-in regulatory oversight and control.

67% of HealthTech professionals expect delays to innovation due to the need to meet regulations, while a further 90% have seen their regulatory costs increase over the last 12 months..

An article from our editorial partner, BioXconomy.

Tarn Brown, Business Transformation Advisor,Columbus UK, BioXconomy.

Sofinnova secures $93m to build tomorrow's medtech pioneers

The Paris-based life sciences VC company’s new fund Sofinnova MD Start IV represents a substantial increase from its predecessor, Sofinnova MD Start III, which closed at €63 million ($71 million). This growth trajectory underscores the expanding appetite for early-stage medtech innovation.

An article from our editorial partner, BioXconomy.

Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy

Life sciences deals surge to $196bn with early-stage asset demand

The first half of 2026 has delivered the strongest run of life sciences dealmaking on record, according to a report published by EY - a long-term partner of LSX and the Pharma BD Leaders Forum.

An article from our editorial partner, BioXconomy.

Nnenna Ohaka, Reporter, Partnering and Investment, BioXconomy.

Fresenius opens €200m gateway fund for emerging biotech talent

The Bad Homburg vor der Höhe-based healthcare group’s fund comes as Europe’s biopharma dealmaking community prepares to descend on Cologne, Germany, for BIO-Europe in November..

An article from our editorial partner, BioXconomy.

Nnenna Ohaka, Reporter, Partnering and Investment, BioXconomy